Development of ALM-488 for nerve and ureter visualization during abdominal surgery

开发用于腹部手术期间神经和输尿管可视化的 ALM-488

• 批准号: 10699258
• 负责人: Brett J. Berman
• 金额: $ 93.72万
• 依托单位: ALUME BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-08 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10699258
• 关键词: Abdomen; Academic Medical Centers; Accidents; Accounting; Anatomy; Binding; Biological Sciences; Burn injury; California; Clinical; Colon Carcinoma; Color; Colorectal Cancer; Colorectal Surgery; Development; Dissection; Dose; Dose Limiting; Dyes; Endoscopes; Excision; Exhibits; Fluorescence; Functional disorder; Goals; Head and Neck Surgery; Head and neck structure; Health; Hiatal Hernia; Hour; Human; Incidence; Individual; Infection; Injury; Intravenous; Intravenous infusion procedures; Label; Laparoscopes; Laparoscopic Surgical Procedures; Length; Light; Lighting; Location; Malignant neoplasm of ovary; Measurement; Methods; Monitor; Morbidity - disease rate; Motor; Multicenter Trials; Nerve; Numbness; Operating Rooms; Operative Surgical Procedures; Paralysed; Participant; Patient-Focused Outcomes; Patients; Pelvis; Peptides; Peripheral Nerves; Pharmaceutical Preparations; Phase; Phase I/II Trial; Postoperative Complications; Postoperative Period; Procedures; Respiratory Diaphragm; Rodent; Safety; Schedule; Sexual Dysfunction; Small Business Innovation Research Grant; Stretching; Structure; Surgeon; System; Texture; Time; Tissues; Toxic effect; Trauma; Tumor Cell Invasion; Tumor Tissue; Universities; Ureter; Visual; Visualization; afferent nerve; autonomic nerve; cancer surgery; chronic pain; clinical candidate; clinical translation; commercialization; contrast enhanced; fluorescence imaging; gastrointestinal; high risk; imaging agent; improved; in vivo; indexing; instrumentation; minimally invasive; nerve agent; nerve damage; nerve injury; nerve supply; novel; open label; patient population; phase 3 testing; phase II trial; preclinical study; preservation; prevent; prospective; protein aminoacid sequence; repaired; research clinical testing; tumor; urinary

PROJECT SUMMARY Fundamental to the goals of surgery are functional preservation of critical nerves and minimization of post- operative patient morbidity. Unfortunately, inadvertent nerve injury during surgery continues to be a major cause of post-surgical patient morbidity due to the inability of surgeons to visualize nerves during surgery. Nerve injury is a frequent postoperative complication of minimally invasive surgeries, leading to significant patient morbidity and long-term consequences that can include chronic pain, numbness, urinary and defecatory dysfunction, sexual dysfunction, and paralysis. Inadvertent intraoperative ureteral injuries additionally contribute to the high rate of postoperative complications in this patient population. Current nerve identification strategies utilize non- quantifiable criteria such as anatomy, texture, color, and relationship to surrounding structures to distinguish nerve or ureter from non-nerve tissues. In instances of trauma, tumor invasion, or infection, nerve identification using the above criteria is especially challenging and often fails to prevent nerve damage. Using white light reflectance, which is the standard mode of illumination in operating rooms, the visual difference between small nerves and adjacent tissue can be imperceptible. There is an unmet need to improve the intraoperative visualization of nerves and ureters to preserve their function and minimize patient morbidity following surgery. There are currently no clinically approved agents that enhance nerve and ureter contrast in the same surgery. Alume Biosciences has developed a first-in-class IV-administered agent for nerve visualization. This candidate, ALM-488, is a peptide dye conjugate that binds motor, sensory, and autonomic nerves in vivo and enables nerve visualization with high nerve to non-nerve contrast with no inherent toxicity. ALM-488 fluoresces at a wavelength that is compatible for potential dual use with Near-infrared (NIR) tumor agents, and thus, is well suited to deliver on the complimentary goals of enhancing tumor tissue and nerve visualization during resections. In preclinical studies, ALM-488 labels both nerve and ureter with high selectivity, both of which can be easily visualized using existing clinically approved endoscopes. Critically, ALM-488 has recently completed clinical testing for nerve delineation in open head and neck surgeries, which demonstrated that ALM-488 is safe and has potential to significantly improve intraoperative, real time nerve identification. In this Direct to Phase II SBIR, Alume Biosciences proposes to evaluate ALM-488 for efficacy to improve nerve and ureter visualization in abdominal laparoscopic surgeries including tumor resection using FDA cleared instrumentation. They will accomplish this with a Phase 2 multi-center trial at the University of California San Diego Health and at Stanford University Medical Center to 1) define the ALM-488 dose in patients undergoing laparoscopic surgeries involving dissection of the 1) diaphragmatic hiatus (Nissen, Toupet, Heller, hiatal hernia repair) and 2) pelvic dissection for colorectal surgery (abdominal perineal resection, rectopexy, proctectomy); and 2) evaluate ALM-488 for efficacy to improve intraoperative nerve and ureter conspicuity. Alume anticipates that clinical translation of ALM-488 will be transformative for minimally invasive surgeries to prevent inadvertent injury and improve post-operative patient outcomes.

项目总结